GLG News by Generic Pharmaceuticals Regulation Experts: Healthcare Consultants

1 in 50,000 compounds makes it to market Haptogen Ltd. is relatively new and would not be expected to have such an expansive arsenal of drug compounds Wyeth will continue on improving its paper systems to accommodate new compounds from Haptogen Ltd.

Two large non-Lilly studies took place which affect the disclosures of Zyprexa® (olanzapine) and Symbyax® in the United States.

Microsoft's HealthVault will store medical information in an encrypted database available via the Web. In addition, there will be access to health information available to the public. Putting secured health data online seems like a great idea provided that personal information remains out of reach of...

I know that Pfizer finally came out with the inhaled insulin after many years of hype. Unfortunately its launch and the product has been a flop, primarily because of the size if the inhaler. It is large and looks like a can of tennis balls. It is difficult for the patient to understand the dosing and...

I disagree with the Reuters article. Tamiflu is a safe and effective drug for the young and elderly population.

A recent Chicago-area study has made it clear that diabetics view the daily-injection routine as being equally as onerous as many of the long-term complications from the uncontrolled disease. In addition to multiple daily injections, diabetic patients usually take several concommitant medications every...

Soma has been around for many years. Now we have a new strength? Probably because there is no generic available on the 250mg.

    Both of Dr. Steven Nissen’s publications are meta-analysis, implying a weakness in their sampling.  In my opinion, more refined studies with larger sample sizes and standardized measurements with Actos, Avandia and placebo or other medications need to be evaluated. ...

Merck is clearly trying to tap into Abbot and Pfizers share of the cardiovascular market. The drug Cordaptive has packaging or formulation issues that spell regulatory delay.

1) The different mechanisms of action for Diovan which reduces blood pressure by targeting angiotensin receptors, and while Tekturna blocks renin, a kidney enzyme that triggers a process in hypertension make them somewhat non-competitive. Tekturna is a good addition to the cardiovascular regime that...